TWCG Announces the Addition of Dr. Daniel Gruener
May 7, 2015
Thievon-Wright Consulting Group, LLC, a subsidiary of ERG Holding Company, LLC is pleased to announce the addition of Dr. Daniel Gruener.
Dr. Gruener, double board certified in psychiatry and pain management, is joining TWCG as Medical Director, Early Phase Services, and will be located in our St. Louis Clinical Trials site working alongside Dr. Rick Mofsen. In addition to his vast experience in psychiatry, Dr. Gruener has conducted early phase studies in Abuse Liability, Pain, Diabetes and Hepatitis, making him an excellent compliment to Dr. Mofsen and St. Louis Clinical Trials. Dr. Gruener comes to us from the former CRI Lifetree which was acquired by PRA last February, where he spent nearly 9 years. During his tenure, he founded the Center for Pain Research and was ultimately responsible for the oversight of a 100 bed early phase research unit.
Dr. Gruener’s career has focused on drug discovery, drug development, drug delivery and patient safety. He has extensive experience as a clinician and has conducted basic science research with novel compounds for both large and small pharmaceutical and biotechnology companies. In addition to clinical research, Dr. Gruener is involved in teaching, clinical practice, andpublishing in the fields of pain management and psychiatry. He has chaired numerous conferences, continuing medical education programs, advisory boards, and similar activities both nationally and internationally, and is a frequent invited lecturer.
We are very excited to have Dr. Gruener on our team of highly experienced investigators and his contributions will further support our position in providing superior early phase development services. Please join us in welcoming Dr. Gruener.